Notice: Undefined index: HTTP_REFERER in D:\CNES\index.php on line 3
Robinul (Glycopyrrolate Tablets): Side Effects, Uses, Dosage, Interactions, Warnings

Robinul Tablets

Medical Editor: John P. Cunha, DO, FACOEP Last updated on RxList: 7/25/2024

Drug Summary

What Is Robinul?

Robinul (glycopyrrolate tablets) is an anticholinergic indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer.

What Are Side Effects of Robinul?

Side effects of Robinul include:

  • blurred vision,
  • drowsiness,
  • decreased sweating,
  • flushing,
  • vomiting,
  • constipation,
  • dry mouth,
  • fast heart rate, and
  • urinary retention.

Seek medical care or call 911 at once if you have the following serious side effects:

  • Serious eye symptoms such as sudden vision loss, blurred vision,tunnel vision,eye painor swelling, or seeing halos around lights;
  • Serious heart symptoms such as fast, irregular, or pounding heartbeats; fluttering in your chest; shortness of breath; and sudden dizziness, lightheadedness, or passing out;
  • Severe headache,confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors.

This document does not contain all possible side effects and others may occur. Check with your physician for additional information about side effects.

Dosage for Robinul

The recommended initial dosage of Robinul is1 mgthree times daily (in the morning, early afternoon, and at bedtime). Some patients may require 2 mg at bedtime to assure overnight control of symptoms. For maintenance, a dosage of 1 mg twice a day is frequently adequate.

Robinul In Children

Safety and effectiveness of Robinul in pediatric patients have not been established.

What Drugs, Substances, or Supplements Interact with Robinul?

Robinul may interact with other medicines such as:

  • other anticholinergic drugs (e.g., tricyclic antidepressants, anti-epileptics, class I antiarrhythmics, antispasmodics, amantadine),
  • drugs that are affected by altered gastrointestinal motility, and
  • solid oral dosage forms of potassium chloride.

Tell your doctor all medications and supplements you use.

Robinul During Pregnancy and Breastfeeding

Tell your doctor if you are pregnant or plan to become pregnant before using Robinul; it is unknown if it would affect a fetus. It is unknown if Robinul passes into breast milk. As with other anticholinergic drugs, glycopyrrolate may cause suppression of lactation. Consult your doctor before breastfeeding.

Additional Information

Our Robinul (glycopyrrolate tablets) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Description for Robinul

Robinul® and Robinul® Forte tablets contain the synthetic anticholinergic, glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3- [(cyclopentylhydroxyphenylacetyl)oxy]-1, 1-dimethylpyrrolidinium bromide.

Robinul tablets are scored, compressed white tablets engraved HPC 200. Each tablet contains:

Glycopyrrolate, USP      1 mg

Robinul Forte tablets are scored, compressed white tablets engraved HORIZON 205. Each tablet contains:

Glycopyrrolate, USP      2 mg

Inactive Ingredients

Dibasic Calcium Phosphate, Lactose, Magnesium Stearate, Povidone, Sodium Starch Glycolate

Uses for Robinul

For use as adjunctive therapy in the treatment of peptic ulcer.

Dosage for Robinul

The dosage of Robinul® or Robinul® Forte should be adjusted to the needs of the individual patient to assure symptomatic control with a minimum of adverse reactions. The presently recommended maximum daily dosage of glycopyrrolate is 8 mg.

Robinul (glycopyrrolate, 1 mg) tablets. The recommended initial dosage of Robinul for adults is one tablet three times daily (in the morning, early afternoon, and at bedtime). Some patients may require two tablets at bedtime to assure overnight control of symptoms. For maintenance, a dosage of one tablet twice a day is frequently adequate.

Robinul Forte (glycopyrrolate, 2 mg) tablets. The recommended dosage of Robinul Forte for adults is one tablet two or three times daily at equally spaced intervals.

Robinul tablets are not recommended for use in pediatric patients under the age of 12 years.

HOW SUPPLIED

Robinul® (glycopyrrolate, 1 mg) tablets are supplied as:

Bottles of 30 NDC 70199-007-30
Bottles of 90 NDC 70199-007-90

Robinul® Forte (glycopyrrolate, 2 mg) tablets are supplied as:

Bottles of 30 NDC 70199-008-30
Bottles of 90 NDC 70199-008-90

Store at controlled room temperature, 20°C to 25°C (68°F to 77°F); excursions permitted to 15°- 30°C (59°- 86°F) [see USP Controlled Room Temperature]. Keep out of reach of children.

Dispense in tight container.

Manufactured for: Casper Pharma LLC, East Brunswick, NJ 08816. Manufactured by: Suven Pharmaceuticals Limited, Telangana, India. Revised: Jun 2021.

Side Effects for Robinul

Anticholinergics produce certain effects, most of which are extensions of their fundamental pharmacological actions. Adverse reactions to anticholinergics in general may include xerostomia; decreased sweating; urinary hesitancy and retention; blurred vision; tachycardia; palpitations; dilatation of the pupil; cycloplegia; increased ocular tension; loss of taste; headaches; nervousness; mental confusion; drowsiness; weakness; dizziness; insomnia; nausea; vomiting; constipation; bloated feeling; impotence; suppression of lactation; severe allergic reaction or drug idiosyncrasies including anaphylaxis, urticaria and other dermal manifestations.

Robinul (glycopyrrolate) is chemically a quaternary ammonium compound; hence, its passage across lipid membranes, such as the blood-brain barrier, is limited in contrast to atropine sulfate and scopolamine hydrobromide. For this reason the occurrence of CNS related side effects is lower, in comparison to their incidence following administration of anticholinergics which are chemically tertiary amines that can cross this barrier readily. To report SUSPECTED ADVERSE REACTIONS, contact Casper Pharma LLC. at 1-844-5-CASPER (1-844-522-7737) or FDA at 1-800- FDA-1088 or www.fda.gov/medwatch.

Drug Interactions for Robinul

There are no known drug interactions.

Warnings for Robinul

In the presence of a high environmental temperature, heat prostration (fever and heat stroke due to decreased sweating) can occur with use of Robinul.

Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy or colostomy. In this instance treatment with this drug would be inappropriate and possibly harmful.

Robinul (glycopyrrolate) may produce drowsiness or blurred vision. In this event, the patient should be warned not to engage in activities requiring mental alertness such as operating a motor vehicle or other machinery, or performing hazardous work while taking this drug. Theoretically, with overdosage, a curare-like action may occur, i.e., neuro-muscular blockade leading to muscular weakness and possible paralysis.

Pregnancy

The safety of this drug during pregnancy has not been established. The use of any drug during pregnancy requires that the potential benefits of the drug be weighed against possible hazards to mother and child. Reproduction studies in rats revealed no teratogenic effects from glycopyrrolate; however, the potent anticholinergic action of this agent resulted in diminished rates of conception and of survival at weaning, in a dose-related manner. Other studies in dogs suggest that this may be due to diminished seminal secretion which is evident at high doses of glycopyrrolate. Information on possible adverse effects in the pregnant female is limited to uncontrolled data derived from marketing experience. Such experience has revealed no reports of teratogenic or other fetus-damaging potential. No controlled studies to establish the safety of the drug in pregnancy have been performed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. As a general rule, nursing should not be undertaken while a patient is on a drug since many drugs are excreted in human milk.

Pediatric Use

Since there is no adequate experience in pediatric patients who have received this drug, safety and efficacy in pediatric patients have not been established.

Precautions for Robinul

Use Robinul with caution in the elderly and in all patients with:

Overdose Information for Robinul

The symptoms of overdosage of glycopyrrolate are peripheral in nature rather than central.

  1. To guard against further absorption of the drug-use gastric lavage, cathartics and/or enemas.
  2. To combat peripheral antichloinergic effects (residual mydriasis, dry mouth, etc.)–utilize a quaternary ammonium anticholinesterase, such as neostigmine methylsulfate.
  3. To combat hypotension–use pressor amines (norepinephrine, metaraminol) i.v.; and supportive care.
  4. To combat respiratory depression–administer oxygen; utilize a respiratory stimulant such as Dopram® i.v.; artificial respiration.

Contraindications for Robinul

Glaucoma; obstructive uropathy (for example, bladder neck obstruction due to prostatic hypertrophy); obstructive disease of the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis, etc.); paralytic ileus; intestinal atony of the elderly or debilitated patient; unstable cardiovascular status in acute hemorrhage; severe ulcerative colitis; toxic megacolon complicating ulcerative colitis; myasthenia gravis. Robinul (glycopyrrolate) tablets are contraindicated in those patients with a hypersensitivity to glycopyrrolate.

Clinical Pharmacology for Robinul

Glycopyrrolate, like other anticholinergic (antimuscarinic) agents, inhibits the action of acetylcholine on structures innervated by postganglionic cholinergic nerves and on smooth muscles that respond to acetylcholine but lack cholinergic innervation. These peripheral cholinergic receptors are present in the autonomic effector cells of smooth muscle, cardiac muscle, the sino-atrial node, the atrioventricular node, exocrine glands, and, to a limited degree, in the autonomic ganglia. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions.

Glycopyrrolate antagonizes muscarinic symptoms (e.g., bronchorrhea, bronchospasm, bradycardia, and intestinal hypermotility) induced by cholinergic drugs such as the anticholinesterases.

The highly polar quaternary ammonium group of glycopyrrolate limits its passage across lipid membranes, such as the blood-brain barrier, in contrast to atropine sulfate and scopolamine hydrobromide, which are non-polar tertiary amines which penetrate lipid barriers easily.

Patient Information for Robinul

No information provided. Please refer to the WARNINGS and PRECAUTIONS sections.

From WebMD Logo

Drugs and Treatment Resources
Featured Centers
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.